宝莱特: 财通证券股份有限公司关于广东宝莱特医用科技股份有限公司定期现场检查报告

Group 1 - The company reported a net profit attributable to shareholders of approximately -71 million yuan for 2024, primarily due to external environment factors, adjustments in business model, and a decrease in orders, leading to reduced operating income and increased management and financial expenses [4] - In October 2024, the company received a warning letter from the Guangdong Securities Regulatory Bureau due to issues related to revenue recognition, construction in progress, goodwill impairment, and internal control, and has actively rectified these issues and submitted a written rectification report [4] Group 2 - The company has established a long-term mechanism to protect its interests, ensuring compliance with information disclosure obligations and preventing the direct or indirect occupation of company funds or resources [2] - The company has complied with relevant regulations regarding the use of raised funds, ensuring that any changes in fund usage are properly disclosed and do not involve high-risk investments during the commitment period [2]